Navigation Links
European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Company's empagliflozin*, an investigational type 2 diabetes treatment
Date:3/26/2013

Prescription Medicines corresponds to 23.5% of its net sales.

For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

About Lilly Diabetes

Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and our continued commitment to providing real solutions – from medicines to support programs and more – to make lives better.

For more information, visit www.lillydiabetes.com.

This press release contains forward-looking statements about empagliflozin* for the treatment of type 2 diabetes. It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date or that empagliflozin* will prove to be commercially successful. For further discussion of these and other risks and uncertainties, pl
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genalyte Announces CE Mark For Maverick(TM) Detection System And Signs On First European Distributors
2. European Commission Designates MST-188 As An Orphan Medicinal Product
3. Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union
4. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
5. SonaCare Medical to Introduce Two New HIFU Products at the European Association of Urology (EAU) Congress
6. European Hearing Aids and Audiology Devices Market
7. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
8. Product Differentiation to Boost European Human Growth Hormones Market, Says Frost & Sullivan
9. BioElectronics Expands European Distribution to Malta
10. Heptares to Present at the 6th Annual European Life Sciences CEO Forum (5-6 March)
11. Cardica Updates Enrollment Progress In European Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will ... the Australian and New Zealand Forensic Science Society,s ... Sciences in Adelaide, Australia . ... concerning the advancements that hyperspectral imaging can bring ... Jeffrey Beckstead , Director of Product Development at ...
(Date:8/29/2014)... British Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the ... fiscal year-end financial statements.  The Company recently changed its ... facilitate an application to list its common stock on ... DelMar,s financial statements as filed with the ...
(Date:8/28/2014)... Aug. 28, 2014 Reportlinker.com announces that ... its catalogue: North America Aesthetic Lasers ... http://www.reportlinker.com/p02343466/North-America-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html North ... to 2020 Summary GlobalData,s new report, ... Outlook to 2020", provides key market data on ...
Breaking Medicine Technology:ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16
... QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today a ... Phase 3 study required for New Drug Application (NDA) ... 140 patients has greater than 90% power to detect ... to enrol additional patients. QRxPharma anticipates completing analysis of ...
... or "Company") (Nasdaq: UNIS, ASX: UNS), today announced that ... clearance from the U.S. Food and Drug Administration (FDA). ... variant of the Unitract™ 1mL Insulin Syringe for which ... syringes which are primarily used by people with diabetes, ...
Cached Medicine Technology:QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo®IR 2QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo®IR 3Unilife Corporation Secures FDA 510k Clearance for the Unitract™ 1mL Tuberculin Syringe 2Unilife Corporation Secures FDA 510k Clearance for the Unitract™ 1mL Tuberculin Syringe 3
(Date:8/30/2014)... Skmen.com, a well-known clothing manufacturer, has announced its promotion ... middle of September, all the company’s new and old ... 30 percent off. , As a matter of ... made and come with quality guarantees. They can certainly ... popular for its fashionable, high quality clothes for men ...
(Date:8/30/2014)... TX (PRWEB) August 30, 2014 Information ... Pros company to introduce better prices to consumers in ... plans can be found when using the open system ... national lookup system available to use this year can ... insurance based on general location and not from medical ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 ... a Spa-on-Wheels which offers the complete spa experience ... inviting lighting and the most important ingredient of ... "the dedicated licensed pro's! People will enjoy the ... continues Kaplan-Pelle. The website reads, "Step into the ...
(Date:8/30/2014)... Denver, Colorado (PRWEB) August 30, 2014 Daily ... Carter, called the Make Him Desire You program, who shows ... heart. , The author of this method says that the ... guys. , The Make Him Desire You review indicates that ... reveals amazing insider advice and his great techniques to make ...
(Date:8/30/2014)... August 30, 2014 Daily Gossip reveals in ... Infection is a method created by Sarah Summer, who can ... The author of this new program actually had to deal ... sufferer to be able to access it, in an all-natural ... determination in finding an effective cure for yeast infection. The ...
Breaking Medicine News(10 mins):Health News:Huge Deals On 2014 Long Casual Dresses Unveiled By Skmen.com 2Health News:Term Life Insurance Rates Now Found Nationally by New Insurer Finder Tool 2Health News:Hands On Mobile Massage and Spa of Long Island Now Offers a Spa-on-wheels 2Health News:Make Him Desire You Review Reveals Powerful Formula to Make a Man Emotionally Addicted 2Health News:Natural Cure for Yeast Infection Review Exposes New Natural Treatment 2
... Celator Pharmaceuticals today announced that new data ... in consolidation treatment for leukemia and of CPX-1 ... agents for the treatment of colorectal cancer were ... American Association for Cancer Research (AACR) in Denver, ...
... REDWOOD CITY, Calif., April 22 AcelRx Pharmaceuticals, ... Phase 2 clinical trial of ARX-02, a proprietary ... pain control. The primary objective of this multicenter, ... tolerability and efficacy of ARX-02 relative to placebo ...
... OAK BROOK, Ill., April 22 The ... of Minnesota have agreed to conditions for ... receive certain services from DeCare Dental following ... certain business functions that DeCare previously performed ...
... on the list. , ... Newport Beach, CA (Vocus) April 22, 2009 ... of four hospitals in Los Angeles and Orange Counties and one of ... as reported by AARP The Magazine. The designation of a "top hospital" ...
... is committed to providing people with skin care ... practical advice and helpful insights are provided by ... devotion to cosmetic dermatology. The content is written ... wide range of practical advice. Key portions of ...
... its commitment to seniors on Medicaid. New Jersey ... Assisted Living Concepts, revealed a history of evictions when ... , WESTBURY, N.Y., April 22 Raphael Weiss, Managing ... ( www.AmberCourtAL.com ), assured that his ...
Cached Medicine News:Health News:Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research 2Health News:Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research 3Health News:AcelRx Announces Initiation of Phase 2 Cancer Breakthrough Pain Program 2Health News:Delta Dental Plans Association and Delta Dental of Minnesota Agree to Conditions Regarding Supplier 2Health News:Hoag named in top 125 hospitals by Consumers' CHECKBOOK as reported by AARP The Magazine 2Health News:Beauty-Doctors Website Provides Dermatologist-Authored Skin Care Information from Experts 2Health News:Amber Court Assisted Living Communities Reaffirms its Commitment to Seniors on Medicaid 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: